- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04927884
A Study of Sacituzumab With Chemoimmunotherapy to Treat Advanced Triple-Negative Breast Cancer After Prior Therapies
Open-Label Phase 1b/2 Study of Sacituzumab Govitecan-Hziy Plus Chemoimmunotherapy for the Treatment of Subjects With Advanced Triple-Negative Breast Cancer After Prior Therapy
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
In part 1 of phase 1b, 3 to 6 subjects will be sequentially enrolled starting at dose level 1 and will be assessed for dose limiting toxicities (DLTs). Dose level cohorts for sacituzumab govitecan-hziy are as follows:
- Dose level 1: Sacituzumab govitecan-hziy (7.5 mg/kg IV)
- Dose level 2: Sacituzumab govitecan-hziy (10 mg/kg IV)
- Dose level 1 (if needed): Sacituzumab govitecan-hziy (5.0 mg/kg IV)
In part 2 of phase 1b, dose expansion will occur when the RP2D has been determined. An additional 4 subjects may be enrolled, for a total of up to 10 subjects at the RP2D. Following part 2 of the phase 1b portion of the study, the Safety Review Committee (SRC) will meet to determine if enrollment into phase 2 should proceed.
In the phase 2 portion of the study, 22 subjects will be enrolled at the RP2D in the first stage of Simon's two stage optimal design. If ≥ 9 of 22 subjects exhibit a confirmed response, the study will proceed to the second stage.
If the study proceeds to the second stage, an additional 41 subjects will be enrolled for a total of 63 subjects in the phase 2. If ≥ 27 of the 63 subjects exhibit a confirmed response, the combination therapy will be considered for further development.
All subjects may receive up to 17 cycles (ie, 51 weeks) of treatment administered in 3-week cycles.
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
California
-
Newport Beach, California, United States, 92663
- Hoag Memorial Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age ≥ 18 years.
- Able to understand and provide a signed informed consent that fulfills the relevant IRB or Independent Ethics Committee (IEC) guidelines.
- Histologically confirmed stage IV TNBC. Subjects must have had at least 2 prior treatments for TNBC. TNBC is defined as breast cancer that lacks estrogen receptor (ER) and progesterone receptor (PgR) expression (both ≤ 1% of tumor cell nuclei), and human epidermal growth factor receptor 2 (HER2) overexpression and/or amplification (IHC 0 or 1+, or IHC 2+ and fluorescence in situ hybridization [FISH]-), according to American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) guideline criteria, as evaluated by local institutions.
- Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 to 2.
- Have at least 1 measurable lesion of ≥ 1.0 cm and/or non-measurable disease evaluable in accordance with RECIST V1.1.
- Ability to attend required study visits and return for adequate follow-up, as required by this protocol.
- Agreement to practice effective contraception for female subjects of child-bearing potential and non-sterile males. Female subjects of child-bearing potential must agree to use effective contraception while on study and for at least 5 months after the last dose of study treatment. Non-sterile male subjects must agree to use a condom while on study and for up to 5 months after the last dose of study treatment. Effective contraception includes surgical sterilization (eg, vasectomy, tubal ligation), two forms of barrier methods (eg, condom, diaphragm) used with spermicide, intrauterine devices (IUDs), oral contraceptives, and abstinence.
Exclusion Criteria:
- Have previously received or are currently receiving treatment with sacituzumab govitecan-hziy.
- Serious uncontrolled concomitant disease that would contraindicate the use of the investigational drug used in this study or that would put the subject at high risk for treatment-related complications.
- Systemic autoimmune disease (eg, lupus erythematosus, rheumatoid arthritis, Addison's disease, autoimmune disease associated with lymphoma).
- History of organ transplant requiring immunosuppression.
- History of or active inflammatory bowel disease (eg, Crohn's disease, ulcerative colitis).
Inadequate organ function, evidenced by the following laboratory results:
- Absolute neutrophil count (ANC) < 1500 cells/mm3.
- Platelet count < 75,000 cells/mm3.
- Hemoglobin < 9 g/dL.
- Total bilirubin greater than the upper limit of normal (ULN; unless the subject has documented Gilbert's syndrome).
- Aspartate aminotransferase (AST [SGOT]) or alanine aminotransferase (ALT [SGPT]) > 2.5 × ULN (> 5 × ULN in subjects with liver metastases).
- Alkaline phosphatase (ALP) levels > 2.5 × ULN (> 5 × ULN in subjects with liver metastases, or >10 × ULN in subjects with bone metastases).
- Serum creatinine > 2.0 mg/dL or 177 μmol/L.
- Uncontrolled hypertension (systolic > 160 mm Hg and/or diastolic > 110 mm Hg) or clinically significant (ie, active) cardiovascular disease, cerebrovascular accident/stroke, or myocardial infarction within 6 months prior to first study medication; unstable angina; congestive heart failure of New York Heart Association grade 2 or higher; or serious cardiac arrhythmia requiring medication.
- Current chronic daily treatment (continuous for > 3 months) with systemic corticosteroids (dose equivalent to or greater than 10 mg/day methylprednisolone), excluding inhaled steroids. Short-term steroid use to prevent IV contrast allergic reaction or anaphylaxis in subjects who have known contrast allergies is allowed.
- Known hypersensitivity to any component of the study medication(s).
- Subjects taking any medication(s) (herbal or prescribed) known to have an adverse drug reaction with any of the study medications.
- Known uridine diphosphate-glucuronosyl transferase 1A1 (UGT1A1) gene polymorphism resulting in reduced function.
- Assessed by the Investigator to be unable or unwilling to comply with the requirements of the protocol.
- Concurrent participation in any interventional clinical trial.
- Pregnant and nursing women. A negative serum pregnancy test during screening and a negative pregnancy test within 72 hours prior to the first dose must be documented before study drug is administered to a female subject of child-bearing potential.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: All subjects
Sacituzumab plus chemoimmunotherapy (cyclophosphamide, N-803, and PD-L1 t-haNK)
|
Dose: 15 μg/kg subcutaneously (SC) Frequency: administered on Day 8 of each cycle (every 3 weeks) Dose: ~2 × 10^9 cells intravenously (IV) Frequency: administered on Days 1 and 8 of each cycle (every 3 weeks) Phase 1b: Dose level 1: Sacituzumab govitecan-hziy (7.5 mg/kg IV) Dose level 2: Sacituzumab govitecan-hziy (10 mg/kg IV) Dose level -1 (if needed): Sacituzumab govitecan-hziy (5.0 mg/kg IV) Phase 2: Dose based on Phase 1b Recommended Phase 2 Dose (IV) Frequency: administered on Days 1 and 8 of each cycle (every 3 weeks) Dose: 25 mg capsules taken twice per day by mouth (PO) Frequency: to be taken Days 1-15 and 15-19 of each cycle (every 3 weeks) |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Phase 1b: Maximum Tolerated Dose (MTD) or Highest Tolerated Dose (HTD)
Time Frame: 12 months
|
Determine the MTD or HTD and designate a recommended phase 2 dose (RP2D)
|
12 months
|
Phase 1b: Safety Profile of sacituzumab plus chemoimmunotherapy
Time Frame: 12 months
|
Incidence of dose limiting toxicities, treatment-emergent adverse events, and serious adverse events
|
12 months
|
Phase 2: Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) V1.1
Time Frame: 48 months
|
Phase 2 primary endpoint
|
48 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Phase 1b:ORR per RECIST V1.1
Time Frame: 48 months
|
Phase 1b secondary endpoint
|
48 months
|
Phase 1b: Progression Free Survival (PFS) per RECIST V1.1
Time Frame: 48 months
|
Phase 1b secondary endpoint
|
48 months
|
Phase 1b: Overall Survival (OS)
Time Frame: 48 months
|
Phase 1b secondary endpoint
|
48 months
|
Phase 1b: Duration of Response (DOR) per RECIST V1.1
Time Frame: 48 months
|
Phase 1b secondary endpoint
|
48 months
|
Phase 1b: Disease Control Rate (DCR) per RECIST V1.1
Time Frame: 48 months
|
Phase 1b secondary endpoint
|
48 months
|
Phase 2: PFS per RECIST V1.1
Time Frame: 48 months
|
Phase 2 secondary efficacy endpoint
|
48 months
|
Phase 2: OS
Time Frame: 48 months
|
Phase 2 secondary endpoint
|
48 months
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Bobby Reddy, MD, ImmunityBio, Inc.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Skin Diseases
- Neoplasms
- Neoplasms by Site
- Breast Diseases
- Breast Neoplasms
- Triple Negative Breast Neoplasms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Antirheumatic Agents
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Antineoplastic Agents, Alkylating
- Alkylating Agents
- Myeloablative Agonists
- Immunoconjugates
- Cyclophosphamide
- Sacituzumab govitecan
Other Study ID Numbers
- QUILT-3.058
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Advanced Triple Negative Breast Cancer
-
National University Hospital, SingaporeRecruitingAdvanced Refractory Solid Tumors | Advanced Triple Negative Breast Cancers | Metastatic Triple Negative Breast CancersSingapore
-
AkesoRecruitingMetastatic Triple-negative Breast Cancer | Locally Advanced Triple-negative Breast CancerChina
-
Fujian Cancer HospitalNot yet recruitingAdvanced Triple Negative Breast CancerChina
-
Melinda TelliPfizer; BioMarin PharmaceuticalCompletedAdvanced Breast Cancer | HER2/Neu Negative | Triple-Negative Breast CancerUnited States
-
First Affiliated Hospital of Shantou University...Guangdong ProCapZoom Biosciences Co., Ltd.Not yet recruitingAdvanced Triple Negative Breast CancerChina
-
Fudan UniversityCompletedAdvanced Triple-Negative Breast CancerChina
-
Nippon Kayaku Co., Ltd.CompletedAdvanced Solid Tumors | Metastatic Triple Negative Breast CancerUnited States
-
Memorial Sloan Kettering Cancer CenterRecruitingBreast Cancer | Metastatic Breast Cancer | Triple Negative Breast Cancer | Triple Negative Breast Neoplasms | Breast Cancer Stage IV | Locally Advanced Breast Cancer | Metastatic Triple-Negative Breast Carcinoma | Locally Advanced Triple-Negative Breast CarcinomaUnited States
-
Novartis PharmaceuticalsCompletedAdvanced Triple Negative Breast Cancer (TNBC) With High TAMsFrance, Italy, Austria, Taiwan, United States, Spain, Australia, Korea, Republic of, Belgium, Germany, Hong Kong, Turkey
-
OncoTherapy Science, Inc.RecruitingRelapsed/Refractory Locally Advanced or Metastatic Breast Cancer and Triple Negative Breast CancerUnited States
Clinical Trials on N-803
-
Masonic Cancer Center, University of MinnesotaCompletedMyelodysplastic Syndrome (MDS) | Acute Myelogenous Leukemia (AML)United States
-
ImmunityBio, Inc.Active, not recruiting
-
Thai Red Cross AIDS Research CentreWalter Reed Army Institute of Research (WRAIR); Henry M. Jackson Foundation...Recruiting
-
Altor BioScienceTerminatedPharmacokineticsUnited States
-
ImmunityBio, Inc.Recruiting
-
ImmunityBio, Inc.Active, not recruitingMelanoma | Renal Cell Carcinoma | Cervical Cancer | Small Cell Lung Cancer | Hepatocellular Carcinoma | Gastric Cancer | Colorectal Cancer | Non-Small Cell Lung Cancer | Head and Neck Squamous Cell Carcinoma | Urothelial Carcinoma | Merkel Cell Carcinoma | Microsatellite Instability | Mismatch Repair DeficiencyUnited States
-
University of MinnesotaWithdrawnHIV Infections | HIV/AIDS | Hiv | AIDS | Aids/Hiv Problem | AIDS and InfectionsUnited States
-
ImmunityBio, Inc.RecruitingNon-muscle Invasive Bladder CancerUnited States
-
University of MinnesotaNational Institute of Allergy and Infectious Diseases (NIAID)CompletedHIV Infections | Hiv | AIDSUnited States
-
ImmunityBio, Inc.Active, not recruiting